PFIZER AND EISAI CONTINUE

ARICEPT COLLABORATION
COMPANIES ALSO ENTER INTO NEW COLLABORATION TO CO-PROMOTE LYRICA IN JAPAN

Thursday, September 24, 2009 - 12:43pm

EDT
(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to
provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption.
Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will
continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will
continue to have an exclusive license to sell Aricept in the other countries where it has rights.
Pfizer will maintain its rights in all countries where it currently commercializes Aricept until July
2022, with the exception of Japan. Pfizer will now return the rights to Aricept in Japan, to Eisai
on December 31, 2012.

Pfizer and Eisai have also entered into a new agreement effective today to co-promote Lyrica in
Japan. Lyrica is under regulatory review in Japan, and assuming approval is granted, this
agreement will continue in force until July 2022.

“Our continued partnership with Eisai is a testament to Pfizer’s commitment to help patients
suffering from Alzheimer’s disease,” said Jeff Kindler, Pfizer Chairman and Chief Executive
Officer. “In addition, we look forward to forging a new alliance with Eisai to help treat
neuropathic pain with our co-promotion of Lyrica in Japan following regulatory approval.”

Pfizer Inc: Working together for a healthier world™

Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new
approaches to better health. We discover, develop, manufacture and deliver quality, safe and
effective prescription medicines to treat and help prevent disease for both people and animals.
We also partner with healthcare providers, governments and local communities around the
world to expand access to our medicines and to provide better quality health care and health
system support. At Pfizer, colleagues in more than 90 countries work every day to help people
stay happier and healthier longer and to reduce the human and economic burden of disease
worldwide.
CODE OF CONDUCT
The first and foremost responsibility of each employee around the world at Pfizer is to
abide by the company's policies on business conduct. Each employee must comply not
only with the letter of these policies, but also with their spirit.

Our policies on business conduct, first written more than 20 years ago, are reviewed
annually to ensure they meet or exceed evolving legal standards and societal
expectations. Colleagues worldwide receive the Summary of Pfizer Policies on Business
Conduct, known as "The Blue Book," which is provided in over 30 languages.

PARTNERING
Today, investment in R&D just isn't enough. Recognizing this change in the healthcare
industry, we pursue partnerships to identify, develop and secure innovation wherever it
occurs.

WORLDWIDE RESEARCH AND

DEVELOPMENT
Strategic partnership in early stage opportunities is a mission of our effort to
deliver on the promise of better health and longer lives.

CORPORATE RESPONSIBILITY
Because everyone deserves access to quality healthcare, we combine
traditional philanthropy with fresh approaches to public health in overlooked
and underserved places.

COMPANY PROFILE (REUTERS)

Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global
biopharmaceutical company. The Company is engaged in the discovery,
development and manufacture of healthcare products. Its global portfolio
includes medicines and vaccines, as well as consumer healthcare products.
The Company manages its commercial operations through two business
segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH
focuses on developing and commercializing medicines and vaccines that
improve patients' lives, as well as products for consumer healthcare. IH
therapeutic areas include internal medicine, vaccines, oncology, inflammation
and immunology, rare diseases and consumer healthcare. EH includes legacy
brands, branded generics, generic sterile injectable products, biosimilars and
infusion systems. EH also includes a research and development (R&D)
organization, as well as its contract manufacturing business. As of December
31, 2016, the Company sold its products in over 125 countries.

The Company's IH brands include Prevnar 13, Xeljanz, Eliquis, Lyrica (the
United States, Japan and certain other markets), Enbrel (outside the United
States and Canada), Viagra (the United States and Canada), Ibrance, Xtandi
and various over-the-counter (OTC) consumer products (Advil and Centrum).
Its EH brands include Lipitor, Premarin family, Norvasc, Lyrica (Europe, Russia,
Turkey, Israel and Central Asia countries), Celebrex, Pristiq and various sterile
injectable products. Its Internal Medicine products include Lyrica (outside all
of Europe, Russia, Turkey, Israel and Central Asia countries), Viagra (United
States and Canada), Chantix/Champix and Eliquis. Its vaccine products include
Prevnar 13/Prevenar 13. Its oncology products include Ibrance, Sutent, Xalkori,
Inlyta and Xtandi. Its inflammation and immunology products include Enbrel
(outside the United States and Canada) and Xeljanz. Its rare diseases products
include BeneFix, Genotropin, and Refacto AF/Xyntha.

The Company's categories and product lines in its consumer healthcare

business include dietary supplements, such as Centrum brands (including
Centrum, Centrum Silver, Centrum Men's and Women's, Centrum
MultiGummies, Centrum VitaMints, Centrum Specialist, Centrum Flavor Burst
and Centrum Kids), Caltrate and Emergen-C; pain management, such as Advil
brands (including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Advil
Menstrual Pain, Children's Advil, Infants' Advil and Advil Migraine) and
ThermaCare; gastrointestinal, such as Nexium 24HR/Nexium Control and
Preparation H, and respiratory and personal care, such as Robitussin, Advil
Cold and Sinus, Advil Sinus Congestion and Pain, Dimetapp and ChapStick.

The Company's Legacy Established Products include products that have lost
patent protection (excluding Sterile Injectable Pharmaceuticals and Peri- Loss
of Exclusivity (LOE) Products), and Peri-LOE Products primarily include Lyrica in
certain developed Europe markets, Pristiq globally, Celebrex, Zyvox and
Revatio; Vfend and Viagra in certain developed Europe markets and Japan,
and Inspra in the European Union (EU). Its Sterile Injectable Pharmaceuticals
include generic injectables and specialty injectables (excluding Peri-LOE
Products). Its Infusion Systems include Medication Management Systems
products composed of infusion pumps and related software and services, as
well as intravenous infusion products, including large volume intravenous
solutions and their associated administration sets. As of December 31, 2016,
the Company had 96 projects in clinical research and development.

The Company's Biosimilars include Inflectra/Remsima (biosimilar infliximab) in

the United States and certain international markets, Nivestim (biosimilar
filgrastim) in certain European, Asian and Africa/Middle East markets, and
Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle East
markets. Its Pfizer CentreOne includes revenues from legacy Pfizer's contract
manufacturing and active pharmaceutical ingredient sales operation, including
revenues related to its manufacturing and supply agreements with Zoetis Inc.,
and revenues from legacy Hospira, Inc.'s One-2-One sterile injectables
contract manufacturing operation.